Suchergebnisse - (Subject:"ritonavir")

PubPharm (14)

1

Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial

enthalten in: Lancet (London, England) | 2020

von RECOVERY Collaborative Group | Horby, P. | Mafham, M. | +24

CommentIn: Lancet. 2020 Oct 24;396(10259):1310-1311. - PMID 33031761

2

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19 : an open-label, randomised, phase 2 trial

enthalten in: Lancet (London, England) | 2020

von Hung, I. | Lung, K. | Tso, E. | +41

CommentIn: Lancet. 2020 May 30;395(10238):1670-1671. - PMID 32401712

3

Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174) : a randomised controlled trial

enthalten in: Lancet (London, England) | 2016

von Nagot, N. | Kankasa, C. | Tumwine, J. | +98

CommentIn: Lancet. 2016 Feb 6;387(10018):513-4. - PMID 26603916

4

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I) : a randomised, open-label trial

enthalten in: Lancet (London, England) | 2015

von Hézode, C. | Asselah, T. | Reddy, K. | +11

CommentIn: Lancet. 2015 Jun 20;385(9986):2443-5. - PMID 25837828

5

Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1 : 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

enthalten in: Lancet (London, England) | 2014

von Raffi, F. | Babiker, A. | Richert, L. | +117

CommentIn: Lancet. 2014 Nov 29;384(9958):1908-10. - PMID 25103175

6

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO) : 48 week results from the randomised open-label phase 3b study

enthalten in: Lancet (London, England) | 2014

von Clotet, B. | Feinberg, J. | van Lunzen, J. | +77

CommentIn: Lancet. 2014 Jun 28;383(9936):2191-3. - PMID 24698484

7

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE) : a randomised, open-label, non-inferiority study

enthalten in: Lancet (London, England) | 2013

von SECOND-LINE Study Group | Boyd, M. | Kumarasamy, N. | +112

CommentIn: Lancet. 2013 Jun 15;381(9883):2062-3. - PMID 23769218

8

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection : a randomised, double-blind, phase 3, non-inferiority trial

enthalten in: Lancet (London, England) | 2012

von DeJesus, E. | Rockstroh, J. | Henry, K. | +10

CommentIn: Lancet. 2012 Jun 30;379(9835):2403-5. - PMID 22748575

9

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2) : two multicentre, double-blind, randomised controlled trials

enthalten in: Lancet (London, England) | 2010

von Eron, J. | Young, B. | Cooper, D. | +108

CommentIn: Lancet. 2010 Jan 30;375(9712):352-4. - PMID 20074790

10

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients : 48 week efficacy and safety results of the CASTLE study

enthalten in: Lancet (London, England) | 2008

von Molina, J. | Andrade-Villanueva, J. | Echevarria, J. | +110

CommentIn: Lancet. 2008 Aug 23;372(9639):604-6. - PMID 18722849